Wiskott-Aldrich syndrome (WAS) is an X-linked primary immunodeficiency disease caused by mutations in the gene encoding the WAS protein (WASp). Here, induced pluripotent stem cells (iPSCs) were derived from a WAS patient (WAS-iPSC) and the endogenous chromosomal WAS locus was targeted with a wtWAS-2A-eGFP transgene using zinc finger nucleases (ZFNs) to generate corrected WAS-iPSC (cWASiPSC). WASp and GFP were first expressed in the earliest CD34 These results demonstrate that the defects exhibited by WAS-iPSC-derived lymphoid cells were fully corrected and suggests the potential therapeutic use of gene-corrected WAS-iPSCs.
INTRODUCTION
Wiskott-Aldrich syndrome (WAS) is a severe X-linked primary immunodeficiency resulting from mutations in the WAS gene; WAS encodes a hematopoietic-specific and developmentally regulated cytoplasmic protein (WASp). WASp is a key regulator of the actin cytoskeleton, specifically regulating actin polymerization and formation of immunological synapses. Within the immune system, WASp deficiency results in well-documented functional defects in mature lymphocytes such as reduced antigenspecific proliferation of T cells and significantly reduced cytotoxic activity by natural killer (NK) cells when exposed to tumor cell lines (Orange et al., 2002) .
Transplantation of hematopoietic stem cells (HSCs) represents a potential therapeutic approach for a variety of hematological disorders. Success in treating WAS via lentiviral-mediated gene delivery has recently been reported (Aiuti et al., 2013; Hacein-Bey Abina et al., 2015) . Although no leukemogenic events were reported in up to 3 years following delivery of gene-modified CD34 + cells, it remains difficult to predict whether any of the unique integration sites (e.g., $10,000 per treated child in Aiuti et al. [2013] ) will result in adverse consequences in the longer term as occurred in the original WAS retroviral gene-therapy trial (Braun et al., 2014) . Thus, development of site-specific targeting strategies for treatment of WAS is warranted.
In this study, we wished to assess whether targeted gene editing of WASp-deficient induced pluripotent stem cells (iPSCs) would result in functional correction of the derived hematopoietic progeny. WAS can be caused by a diversity of mutations distributed across all 12 exons. To provide a gene correction solution potentially applicable to most, if not all, WAS patient cells, we used zinc finger nuclease (ZFN)-mediated, site-specific, homology-directed repair (HDR) to target the integration of a corrective WAS gene sequence into the endogenous WAS chromosomal locus. We hypothesized that utilizing the endogenous WAS promoter, the natural WAS chromatin environment, and transcription regulatory signals, would provide for a physiologically appropriate WAS transgene expression.
RESULTS

Derivation and Characterization of WAS-iPSCs
Skin fibroblasts were obtained from a WAS patient carrying the 1305 insG WAS mutation. This single-base-pair insertion in exon 10 of the WAS gene would be predicted to yield a WAS protein (WASp) frameshifted at amino acid 424, outof-frame throughout the C-terminal VCA (verprolin homology, cofilin homology, acidic) domains critical for WASp-dependent actin polymerization and immunological synapse formation, and to conclude in a premature termination at position 493. Patients with the 1305 insG WAS mutation exhibit negligible WASp expression in hematopoietic cells, likely due to instability or degradation of the protein (Wada et al., 2003) .
Following reprogramming, we verified the WAS 1305 insG mutation in WAS-iPSC clones, and confirmed characteristic pluripotent stem cell antigen expression, a normal karyotype, and pluripotency (Figures S1A-S1D). Quantitative transcriptional profiling of WAS-iPSCs revealed a gene expression pattern highly similar to human embryonic stem cells (hESCs) (line WA09) ( Figure S1E ).
Endogenous Targeted Integration: WAS-iPSC Gene
Correction WAS-iPSCs were corrected via ZFN-mediated HDR as shown in Figure 1A . The targeting strategy was such that successful HDR-mediated targeted integration (TI) of the WAS exon 2-12 cDNA (WAS 2-12 ) within intron 1 would result in normal transcriptional initiation at exon 1 (directed by the endogenous upstream transcriptional regulatory sequences); splicing from the splice donor at the end of exon 1 to the splice acceptor at the start of the WAS 2-12 cDNA to yield the WAS-2A-GFP mRNA; the inclusion of GFP in the WAS 2-12 -2A-GFP cassette was to enable tracking of WASp-expressing cells. A loxP-flanked pgkpuroTK-selectable cassette was inserted just downstream of the transgene sequences in order to permit puromycinmediated selection of initial clones as well as subsequent fialuridine (FIAU)-mediated selection of Cre-excised clones.
Successfully targeted puromycin-resistant clones were first identified by PCR amplification utilizing primers located outside the donor sequences and further confirmed by DNA sequencing (data not shown). Southern blot analysis utilizing the pgk-puroTK sequences as probe, confirmed the intended TI within the WAS locus, and the absence of off-target integrations ( Figure S2A ). Transient expression of Cre-recombinase, followed by FIAU selection, was utilized to excise the pgk-puroTK-selection cassette. The corrected WAS (cWAS) iPSCs, both prior to and following Cre-mediated excision of the selection cassette, retained a normal karyotype ( Figure S2B ) and pluripotency (Figure S2C) . Comparative genomic hybridization (CGH) and whole-exome sequencing were performed on WAS and cWAS-iPSCs to determine whether the targeted correction methodology resulted in unanticipated changes to the chromosomal DNA. The results of these analyses are presented in Tables S1-S3 . These data indicate that the cWAS-iPSCs were generated without any apparent deleterious mutation that could cloud the interpretation of further experiments. Figure 1D ).
Restoration of WASp Expression in cWAS-iPSCDerived Hematopoietic Cells
In order to assess restoration of WASp expression in the cWAS-iPSC-derived cells, we first assayed GFP expression in the in vitro differentiation cultures. GFP expression, albeit at low levels, was clearly present in cWAS-iPSCderived CD34 + CD43 + CD45 À hematopoietic progenitors and in all hematopoietic lineages including myeloid, erythroid, and megakaryocytic lineages ( Figure 2A Figure 2B ). In contrast, cWAS-derived hematopoietic cells expressed the transgenic transcript that correlated with expression of the GFP transcript ( Figure 2B ). Sequencing confirmed that the WAS mRNA expressed by the cWAS CD34 + CD43 + cells was of a WT sequence (i.e., not the mutant 1305 insG) ( Figure 2C ), and derived from the integrated WAS 2-12 transgene (i.e., included a silent C > A substitution at position 995) ( Figure 2C (Figures 3A and 3B ). This deficiency in NK cell development for WAS progenitors was consistently observed using either OP9-DL1 ( Figure 3A) or OP9-DL4 (data not shown) stromal cells to promote NK cell development. As expected for transgene-corrected cells, cWASderived NK cells expressed both GFP ( Figure 3C ) and the WAS transgene ( Figure 3D ). Restoration of WASp expression was confirmed both by FACS ( Figure S4A ) and western blot ( Figure 3E ).
We were able to expand the culture-generated NK cells including the few NK cells generated in the WAS-initiated cultures sufficiently to perform a functional analysis on these cells. WAS progenitor-derived NK cells exhibited significant functional deficits in comparison with both cWAS-and hESC-derived NK cells: upon stimulation with K562 cells, cWAS-and hESC-derived NK cells upregulated production of interferon-g (IFNg) and tumor necrosis factor alpha (TNFa); this response to stimulation was not exhibited by WAS-derived NK cells ( Figure 3F ). This indicates that the defect exhibited by WAS-iPSC-derived NK cells is functionally restored in transgene WASpexpressing NK cells. IFNg and TNFa were increased in both WAS-and cWAS-derived NK cells on WASp-independent activation by phorbol myristate acetate/ionomycin ( Figure S4B ).
cWAS-iPSC-Derived Progenitors Are Fully Competent in Generation of T Cells
We previously reported the ability to derive functional T cells from hESCs (Timmermans et al., 2009) Figure 4B , representative plots are shown from a total of 12-14 independent experiments in which WA01, WAS, and cWAS were cultured and tested head-tohead: at day 14 CD5 + CD7 + T precursor cells were generated in all three cultures. However, later, only few CD4 + CD8 + double-positive precursors (day 28) and CD3 + cells (day 33) are generated in the WAS culture, whereas these cells are present in the control hESC WA01 and the cWAS cultures. This deficit in generation of double-positives and CD3 + T cells was not specific to a single WAS-iPSC clone, but was exhibited by two other mutant WAS clones examined. A summary of the data is shown in Figure 4C . Again the data show no significant difference in generation of CD5 + CD7 + T lineage committed precursors between WAS and cWAS (p = 0.834, NS), although the difference with WA01 was significant (p = 0.016). The deficit of WAS relative to cWAS and WA01 was clearly evident in derivation of both CD4 + CD8 + (p = 0.008 and p = 0.013, respectively) and CD3 + T cells (p = 0.002 and p = 0.05, respectively).
Expression of WASp protein throughout T cell differentiation is evidenced by GFP expression in the various T lineage populations derived from the cWAS-iPSCs ( Figure 4D ). Thus, TI of the WAS transgene in WAS-iPSCs restored development of both CD4 + CD8 + and CD3 + T cells.
DISCUSSION
In this study, we demonstrate the successful, sequence-specific correction of WAS-iPSCs via TI of a WAS transgene into the endogenous WAS locus. We chose to target integration of the WAS 2-12 half-gene into intron 1 of the WAS locus with a view toward potentially providing correction for all WAS mutations; for exon 1 mutations, targeted iPSC clones also incorporating the donor WT exon 1 would be utilized. This report provides proof-of-concept data for the potential utility of WASp-deficient iPSCs corrected using sitedirected gene editing. Correcting the WAS gene mutations in patient-specific iPSCs versus primary HSCs, has two distinct advantages. The first potential advantage is the ability to comprehensively sequence the corrected iPSC clones to rule out any untoward genetic changes. As a first step toward this end, we compared the WAS and cWASiPSCs via whole-exome sequencing and CGH to identify potential consequences of the ZFN-mediated gene editing, Cre-mediated excision, and/or extended iPSC culture. Although some differences were observed (e.g., amplifications or deletions uniquely present in either WAS or cWAS in Table S1 , non-synonymous coding variants in Table S2 ), we did not observe any generation of mutations that we could directly attribute to the ZFN-mediated gene editing. The second potential advantage is that transplantation of corrected iPSC-derived HSCs will result in patients receiving a genetically homogeneous population of corrected cells. Derivation of transplantable HSCs from hESCs/human iPSCs (hiPSCs) remains very inefficient and challenging (Kaufman, 2009; Slukvin, 2013) . Although recent studies suggest strategies to improve generation of transplantable HSC from human pluripotent stem cells (Gori et al., 2015) , these studies need to be confirmed with a demonstration of long-term, multi-lineage HSC engraftment. Non-random X-inactivation of the WAS gene in female carriers and somatic reversion suggest the possibility of a selective advantage in vivo for corrected blood cells at the level of T cell precursors, common lymphoid progenitor cells, and perhaps even at a more primitive stage (Davis et al., 2008; Wengler et al., 1995) . Thus, it may be sufficient to deliver to patients in-vitrogenerated T cell precursors/progenitors from corrected iPSC.
Interestingly, this study of WASp-deficient iPSCs, in comparison with their corrected cWAS-iPSC counterparts, revealed not only the expected functional defects in certain iPSC-derived hematopoietic progeny (e.g., NK cells), but (Park et al., 2004) . These findings led Park et al. to propose that WASp was important in the initial development and maturation of lymphocytes. Studies of WAS knockout mice (Snapper et al., 1998; Zhang et al., 1999) have also identified a significantly reduced number of peripheral blood T lymphocytes. Importantly, Zhang et al. (1999) (Westerberg et al., 2008) . Importantly, WAS knockout mice expressing a WASp DVCA transgene exhibited severe impairment in thymopoiesis, with a clear impairment in differentiation of CD4 À CD8 À thymocytes (Zhang et al., 2002) .
We note that this study was limited to iPSCs derived from one WAS patient and one WAS genotype (1305 insG). The WAS 1305 insG mutation is predicted to produce a WASp lacking the C-terminal VCA domain. The aforementioned publication by Zhang et al. (2002) suggested the possibility that enforced expression of WASp DVCA functions in a dominant-negative manner to suppress successful thymic T cell development. Although we were not able to detect residual expression of the mutant frameshifted, truncated WASp in WAS-iPSC-derived HPCs, it remains a possibility that it exists at a very low level, and thus contributed to our observed defective in vitro T cell development. The majority of the experiments directly compared one corrected WAS-iPSC clone with the mutant WAS-iPSC clone from which it was derived; to convince ourselves that the inability to generate T cells was not a clone-specific defect but rather was due to non-functional WASp, we verified the T cell development deficiency with two other WASiPSC clones derived from the same donor fibroblasts (Figure 4C ). Both the WAS 2-12 transgene and the GFP reporter distinguished the cWAS-iPSCs from the WAS-iPSCs. It is conceivable that GFP expression, albeit at a low level, could have affected the quantitative comparison between cWAS and WAS. However, we note that the statistically significant defects observed for NK and T cell development were quite specific, not seen for example in derivation of endothelial (Lutskiy et al., 2008; Wada et al., 2003) . The revertant genotypes in these patients re-establish expression of a WASp including the VCA domains. These data indicate that restoration of expression of a WASp including the VCA domain, whether by intentional gene correction (as done in the present study) or by reversion, confers a strong selective advantage to T cells. It is generally accepted that a strong selective advantage for revertant cells operates at the level of mature peripheral T cells in their transition, on exposure to antigen, from naive to memory T cells. Our data, together with results from some, but not all, of the WAS knockout mouse models summarized above, suggest that an additional selective advantage for corrected cells possibly exists at a much earlier stage, during T cell development in the thymus. This latter possibility, consistent with a polyclonal T cell receptor (TCR) repertoire exhibited by revertant WAS cells having the same revertant genotype (Wada et al., 2003) , would have implications both for somatic reversion and for transplantation of corrected WAS-iPSC-derived T cell precursors.
EXPERIMENTAL PROCEDURES iPSC Generation and Characterization
The WAS fibroblast cell line GM01598 (NIGMS Human Genetic Cell Repository, Coriell Institute for Medical Research) was transduced with pMXs retroviruses expressing OCT4, SOX2, KLF4, NANOG, and c-MYC. iPSC colonies were subsequently identified based on morphology and live-cell staining for Tra-1-60 and Tra-1-81. Pluripotency was assayed by teratoma formation; animal experimentation was overseen by the University of Texas Health Science at Houston Animal Welfare Committee.
ZFN-Mediated Correction
ZFN plasmids (pVax15755 and pVax15724) targeted WAS intron 1 sequences 5 0 -CCT TTG GGC CCA tga ctG TCA TGA GGC AGg AAG GAC-3 0 (spacer sequences in lower case). iPSCs were nucleofected with ZFNs together with a donor construct which included wt WASex2-12 cDNA linked to a GFP reporter via 2A peptide sequences, the bovine growth hormone pA sequences, followed by a loxP-flanked puro-TK selection cassette.
Generation of Hematopoietic Progenitor Cells
hESC and hiPSC were dissociated using TrypLE Select and resuspended in APEL medium supplemented with BMP-4, VEGF, SCF, and Y-27632. 5,000-7,000 cells were transferred into one well of a 96-well plate and centrifuged at 480 3 g. Following 3-4 days of differentiation, individual EBs were transferred onto OP9 stromal cells and cultured for an additional 8 days in the presence of the cytokines above.
Generation of NK Cells
Sorted CD34 + CD43 + progenitors derived from each cell line were seeded at 3 3 10 4 to 5 3 10 4 cells per well onto 24-well plates pre-coated with live OP9-DL1. Cells were maintained in NK cell differentiation medium including 15% heat-inactivated human AB serum, SCF, IL-7, IL-15, Flt3 ligand, and IL-3 (first week only). Cells were cultured in this system for 28-32 days.
T Cell Differentiation
The T cell protocol was based on the protocol described by Timmermans et al. (2009) with minor modifications. Briefly, day 12 spin EBs were dissociated and cells were resuspended in minimum essential medium alpha supplemented with 20% fetal bovine serum, SCF, Flt3 ligand, and rhIL-7. Cells were transferred onto subconfluent OP9-DL1 feeder layers. Every 5-7 days, cells were transferred on a fresh OP9-DL1 monolayer, for up to 6 weeks. Flow cytometric analysis was performed on days 14, 21, 28, and 33, plus or minus 2 days.
